This 2026 comprehensive guide covers five core ERR‑family research tool compounds: pan‑ERR agonists SLU‑PP‑915, SLU‑PP‑332; subtype‑selective ERRβ/γ agonists DY131 (CAS:95167‑41‑2), GSK4716 (CAS:101574‑65‑6); and ERRα inverse agonist XCT‑790 for control experiments.
Estrogen‑related receptors (ERRα, ERRβ, ERRγ) are orphan nuclear receptors governing PGC‑1α‑driven mitochondrial biogenesis, fatty‑acid oxidation and exercise‑adaptive gene programs, widely studied as exercise‑mimetic targets for sarcopenia, heart failure and metabolic disorder pre‑clinical models.
This article compares CAS registry numbers, scaffold evolution & SAR, receptor selectivity, pharmacokinetic pros & cons, in‑vivo animal findings and practical experimental selection guidance. SLU‑PP‑332 represents the first‑generation pan‑ERR tool with poor oral bioavailability, while boronic‑acid modified SLU‑PP‑915 delivers improved metabolic stability for cardiac research. DY131 and GSK4716 serve as ERRβ/γ‑only agonists; XCT‑790 is used for ERRα loss‑of‑function validation.
All substances are pre‑clinical research‑only chemicals. No human clinical data is available. Not intended for human consumption.